Apgujeong Rolls Royce hit-and-run victim dies after 4 months in coma
Samsung sets up control tower for new growth drivers
South Korea warns tit-for-tat action over North Korea’s border buildup
12 foreigners nabbed on suspicion of drug use
Korea to start hiring E-9 visa foreign workers in restaurants
Samsung Bioepis seeks approval for biosimilar of cancer drug in EuropeBy 박한나
Published : Oct. 4, 2016 - 16:51
According to Samsung’s biotech unit, European Medicines Agency has accepted for review its application to sell SB3, its biosimilar of Herceptin.
“If SB3 receives an approval in Europe, it will contribute to improving the quality of female patients’ lives as treatment opportunities through breast cancer drug can be enhanced,” the firm’s CEO Ko Han-seung said.
SB3 is the first anti-cancer drug that was submitted for regulatory approval in Europe by Samsung Bioepis.
Swiss-based Roche recorded sales of the drug totaling $3.49 billion in the first half of 2016.
By Park Han-na (firstname.lastname@example.org)
Yoon apologizes to nation for failure to host 2030 World Expo
S. Korea may restore disarmed guard post: sources
Yoon orders increased defense of public digital infrastructure